Cornerstone Pharmaceuticals Commences Phase I Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma

CRANBURY, N.J., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL). CPI-613 is the company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy-production pathways in cancer cells by targeting mitochondrial metabolism.

Steve Carchedi, Chief Executive Officer of Cornerstone, said, "Initiating this Phase I trial marks the fourth ongoing trial evaluating our lead compound CPI-613 in advanced hematologic malignancies and overall the eighth study being sponsored by notable, National Cancer Institute-designated comprehensive cancer center, Wake Forest Baptist Medical Center. Furthermore, this study represents the continued interest in CPI-613 by the medical community as a unique approach to fighting cancer by blocking the energy producing pathways that support the growth and development of many cancer cells. We look forward to the active enrollment of B-cell Non-Hodgkin Lymphoma patients in this study as we seek to demonstrate the potential of our lead product candidate as part of a combination therapy."

NHL is the most common cancer of the lymphatic system, a part of the immune system, with more than 320,000 Americans suffering from the disease and over 65,000 cases diagnosed each year in the United States. i  B-cell NHL is the most common form of NHL, comprising more than 85% of all NHL cases. i

The single site study, sponsored by Wake Forest Baptist Medical Center and in collaboration with the National Cancer Institute, is a Phase I, open label, dose-escalating study designed to establish the maximum tolerated dose of CPI-613 when used in combination with bendamustine and rituximab. Secondary outcomes including response rate, overall survival rate, disease control rate and progression-free survival will also be assessed.  

Bendamustine is a chemotherapy drug that has shown single agent activity in heavily pretreated patients with rituximab-refractory (resistant), indolent NHL, showing an overall response rate of approximately 77% in clinical trials. ii An immunotherapy agent, rituximab was the first monoclonal antibody approved for cancer treatment. iii  It targets a specific antigen called CD-20 found on most B-cell lymphomas ii and has been shown to result in a 40-50% response rate in patients who relapse with indolent B-cell lymphomas. iv

Zanetta Lamar, MD, of Wake Forest Baptist Medical Center and the Principal Investigator for the trial, commented, "Survival rates for Non-Hodgkin Lymphoma differ extensively and largely depend on  lymphoma type, stage and age of the patient. The disease can be devastating for patients, which is reflected in an overall 5-year relative survival rate of approximately 69% and a 10-year relative survival rate of approximately 58%. v In this study, our goal is to determine if the combination of chemotherapy, immunotherapy and CPI-613 as a targeted anti-cancer metabolism therapy is effective and safe for patients with relapsed of refractory B-cell Non-Hodgkin Lymphoma."   

CPI-613 is the lead drug candidate from Cornerstone's proprietary AEMD platform. Cornerstone's AEMD drug platform disrupts the metabolism (energy producing) pathways that support the growth and development of many types of cancer cells. CPI-613 has been shown in-vitro to be highly selective in inducing the simultaneous inhibition of two key mitochondrial enzymes involved in cancer cell metabolism: pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH). Disruption of PDH and KGDH function cuts off the tumor's energy supply, culminating in cell death. CPI-613 is currently being evaluated in several Phase I, I/II and II human clinical trials in solid tumors and hematological malignancies.

About Wake Forest Baptist Medical Center

Wake Forest Baptist Medical Center ( wakehealth.edu ) is a fully integrated academic medical center located in Winston-Salem, N.C. The institution comprises Wake Forest School of Medicine , a leading center for medical education and research; Wake Forest Baptist Health , the integrated clinical structure that includes nationally ranked Brenner Children's Hospital ; Wake Forest Innovations , which promotes the commercialization of research discoveries and operates Wake Forest Innovation Quarter , an urban research and technology park; plus a network of affiliated community hospitals, physician practices, outpatient services and other medical facilities. Wake Forest Baptist clinical programs and the School of Medicine are regularly ranked among the best in the country by U.S. News & World Report.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. The company's unique approach to targeting cancer metabolism has led to two distinct technology platforms: altered energy metabolism directed, or AEMD, compounds and an Emulsiphan lipid nanoemulsion based drug delivery system.

Currently, Cornerstone's deep oncology portfolio of clinical trials evaluating CPI-613 at notable institutions includes ongoing studies in both hematologic malignancies and in solid tumors. Overall, CPI-613 has been shown to have broad utility in both solid tumors and hematologic malignancies.

For more information, visit www.cornerstonepharma.com .

This release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

References

i  Lymphoma Research Foundation. "Non-Hodgkin Lymphoma." Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaO...g#Overview

ii Journal of Clinical Oncology. "Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study." 2008. Available online: http://jco.ascopubs.org/content/26/2/204.full

iii University of Maryland Medical Center. "Non-Hodgkin Lymphoma." Available at: http://umm.edu/health/medical/reports/article...s-lymphoma

iv National Cancer Institute. "Treatment for Indolent, Recurrent Adult NHL."  Available at: http://www.cancer.gov/cancertopics/pdq/treatm...nal/page10

v American Cancer Society. "Non-Hodgkin Lymphoma." Available at: http://www.cancer.org/acs/groups/cid/document...26-pdf.pdf

Investor Contacts: David Burke The Ruth Group (646) 536-7009 Media Contact: Kirsten Thomas The Ruth Group (646) 536-7014 Marguerite Beck Senior Manager, National Media Relations Wake Forest Baptist Medical Center (336) 716-2415; (fax) 336-716-6841

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 19

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 287

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 78

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

John T Kim Expands Holdings with $9.65M in Amkor Tech Stock

Updated Category News Views 197

John T Kim Makes Significant Investment in Amkor Tech In a recent SEC filing, substantial insider trading activity was reported, showing that John T Kim, who holds a 10% stake in Amkor Technology Inc. (NASDAQ: AMKR), has acquired shares worth approximately $9.65 million. This key transaction was disclosed in a Form 4 filing, indicating Kim's commitment to the company amid...

Continue Reading
Delcath Systems: Recent Financial Gains and Future Growth Prospects

Updated Category News Views 154

Delcath Systems Secures Significant Funding Delcath Systems, Inc. (NASDAQ:DCTH) is making headlines with the successful exercise of Series E and E1 warrants, bringing in a notable $16.3 million. This funding marks a strategic move for the company, especially following a private placement that took place a few years ago. The timing of this financial boost couldn't be...

Continue Reading
Resolver's Innovative CSAM Detection Service Launch Explained

Updated Category News Views 348

Resolver Launches Pioneering Service for CSAM Detection Resolver, a leading provider of trust and safety intelligence, has introduced an innovative Unknown CSAM Detection Service. This service empowers platforms and services with the capability to identify and classify unknown child sexual abuse material (CSAM) with high precision. Identifying the Challenge in the Digital...

Continue Reading
HanesBrands Finalizes Sale of Champion Business to Authentic Brands

Updated Category News Views 151

HanesBrands Inc. (NYSE: HBI) wrapped up the sale of its global Champion business to Authentic Brands Group, shifting ownership of key intellectual property and assets associated with the brand. Transaction Impact: Simplification or Just Smoke? This deal isn't just another footnote in corporate history; it's a bold stroke by CEO Steve Bratspies who underscored that this...

Continue Reading
NVIDIA's Options Activity: Insights and Market Projections

Updated Category News Views 192

NVIDIA's Options Activity: Insights and Market Projections Financial giants have made a strong bullish move on NVIDIA. An analysis of options history for NVIDIA (NASDAQ: NVDA) revealed a significant number of unusual trades, indicating a growing interest among large-scale investors. As we dig deeper, we find that 45% of traders favor a bullish outlook, while 40% express...

Continue Reading